肌肉丢失与COPD住院患者不良结局相关:全国趋势分析
基于美国2011年全国住院患者数据库,分析174 808例COPD急性加重住院患者,其中7.4%伴有肌肉丢失表型。肌肉丢失表型与更高的院内死亡率(14.6% vs 5.7%,P<0.001)、更长住院时间(13.3+17.1 vs 5.7+7.6,P<0.001)和更高中位住院费用(13 947 vs 6610美元,P<0.001)相关。多因素回归显示肌肉丢失表型使死亡率增加111%、住院时间增加68.4%、直接医疗费用增加83.7%。
要点
- COPD急性加重住院患者中肌肉丢失表型发生率为7.4%。
- 肌肉丢失表型与院内死亡率、住院时间和住院费用显著升高独立相关。
- 临床应关注COPD患者骨骼肌丢失的评估与管理。
核心结论
- COPD急性加重住院患者若伴有肌肉丢失表型,其院内死亡率、住院时间和医疗费用均更高。
研究设计与样本
- 回顾性分析美国2011年全国住院患者数据库(NIS),纳入174 808例COPD急性加重住院患者。
主要发现
- 12 977例(7.4%)患者伴有肌肉丢失表型的次要诊断。
- 肌肉丢失表型组院内死亡率为14.6%,无肌肉丢失组为5.7%(P<0.001)。
- 肌肉丢失表型组住院时间13.3+17.1天,无肌肉丢失组5.7+7.6天(P<0.001)。
- 肌肉丢失表型组中位住院费用为13 947美元,无肌肉丢失组为6610美元(P<0.001)。
- 多因素回归显示肌肉丢失表型使死亡率增加111%(95%CI:2.0-2.2,P<0.001),住院时间增加68.4%(P<0.001),直接医疗费用增加83.7%(P<0.001)。
临床怎么用
- 对COPD急性加重住院患者应评估骨骼肌丢失情况,以识别高危人群。
- 伴有肌肉丢失表型的COPD患者可能需要更密切的监测和资源规划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: COPD is the third most common cause of death worldwide and fourth most common in the United States. In hospitalized patients with COPD, mortality, morbidity and healthcare resource utilization are high. Skeletal muscle loss is frequent in patients with COPD. However, the impact of muscle loss on adverse outcomes has not been systematically evaluated. We tested the hypothesis that patients hospitalized for COPD exacerbation with, compared to those without, a secondary diagnosis of muscle loss phenotype (all ICD-9 codes associated with muscle loss including cachexia) will have higher mortality and cost of care. METHODS: The NIS database of hospitalized patients in 2011 (1 January-31 December) in the United States was used. The impact of a muscle loss phenotype on in-hospital mortality, LOS and cost of care for each of the 174 808 hospitalizations for COPD exacerbations was analysed. RESULTS: Of the subjects admitted for a COPD exacerbation, 12 977 (7.4%) had a secondary diagnosis of muscle loss phenotype. A diagnosis of muscle loss phenotype was associated with significantly higher in-hospital mortality (14.6% vs 5.7%, P < 0.001), LOS (13.3 + 17.1 vs 5.7 + 7.6, P < 0.001) and median hospital charge per patient ($13 947 vs $6610, P < 0.001). Multivariate regression analysis showed that muscle loss phenotype increased mortality by 111% (95% CI: 2.0-2.2, P < 0.001), LOS by 68.4% (P < 0.001) and the direct cost of care by 83.7% (P < 0.001) compared to those without muscle loss. CONCLUSION: In-hospital mortality, LOS and healthcare costs are higher in patients with COPD exacerbations and a muscle loss phenotype.
引用
- Attaway AH, Welch N, Hatipoğlu U, et al. Muscle loss contributes to higher morbidity and mortality in COPD: An analysis of national trends. Respirology. 2020. PMID: 32542761. doi:10.1111/resp.13877
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。